Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: A promising approach for the treatment of defective telomerase disorders

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 91, Issue , 2015, Pages 91-102

  Egusquiaguirre, Susana P ^a,b   Manguán García, Cristina ^c   Pintado Berninches, Laura ^c   Iarriccio, Laura ^c,d   Carbajo, Daniel ^b,e,f   Albericio, Fernando ^b,e   Royo, Miriam ^b,f   Pedraz, José Luís ^a,b   Hernández, Rosa M ^a,b   Perona, Rosario ^c   Igartua, Manuela ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d Advanced Projects Division   (Spain)

^e INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biodegradable nanoparticles; Cell penetrating peptides; Dyskeratosis congenital; GSE24.2 peptide; Polycations; Telomerase reactivation

Indexed keywords

CELL PENETRATING PEPTIDE; GSE24.2 PEPTIDE; MACROGOL 400; POLYGLACTIN; UNCLASSIFIED DRUG; BIOMATERIAL; CELL CYCLE PROTEIN; DELAYED RELEASE FORMULATION; ENZYME ACTIVATOR; LACTIC ACID; MACROGOL DERIVATIVE; NANOPARTICLE; NUCLEAR PROTEIN; PEPTIDE FRAGMENT; POLY(LACTIC-GLYCOLIC ACID)-POLY(ETHYLENEGLYCOL) COPOLYMER; POLYAMINE; POLYCATIONS; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RECOMBINANT PROTEIN; TELOMERASE;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERIZATION; PROTEIN STRUCTURE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; CELL CULTURE; CELL LINE; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DEFICIENCY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DYSKERATOSIS CONGENITA; GENETICS; METABOLISM; PHYSICAL CHEMISTRY; PROTEIN STABILITY; THERAPEUTIC USE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL TRANSPORT; CELL CYCLE PROTEINS; CELL LINE; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG STABILITY; DYSKERATOSIS CONGENITA; ENZYME REACTIVATORS; HUMANS; LACTIC ACID; MICE; NANOPARTICLES; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PHYSICOCHEMICAL PHENOMENA; POLYAMINES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; POLYGLYCOLIC ACID; PROTEIN STABILITY; RECOMBINANT PROTEINS; TELOMERASE;

EID: 84923239298     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.01.028     Document Type: Article

References (45)

1. S.A. Savage, and B.P. Alter Dyskeratosis congenita Hematol. Oncol. Clin. North Am. 23 2 2009 215 231
2. M. Bessler, D.B. Wilson, and P.J. Mason Dyskeratosis congenita FEBS Lett. 584 17 2010 3831 3838
3. I. Dokal, Dyskeratosis congenita, in: American Society of Hematology Education Program, vol. 2011, 2011, pp. 480-486.
4. J. de la Fuente, and I. Dokal Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation Pediatr. Transplant. 11 6 2007 584 594
5. A.J. Walne, and I. Dokal Advances in the understanding of dyskeratosis congenita Br. J. Haematol. 145 2 2009 164 172
6. W. Palm, and T. de Lange How shelterin protects mammalian telomeres Annu. Rev. Genet. 42 2008 301 334
7. E.H. Blackburn Structure and function of telomeres Nature 350 6319 1991 569 573
8. N.S. Young Telomere biology and telomere diseases: implications for practice and research ASH Educ. Progr. Book 1 2010 30 35
9. J.L. Osterhage, and K.L. Friedman Chromosome end maintenance by telomerase J. Biol. Chem. 284 24 2009 16061 16065
10. S.B. Cohen, M.E. Graham, G.O. Lovrecz, N. Bache, P.J. Robinson, and R.R. Reddel Protein composition of catalytically active human telomerase from immortal cells Science (New York, N.Y.) 315 5820 2007 1850 1853
11. R.J. O'Sullivan, and J. Karlseder Telomeres: protecting chromosomes against genome instability Nat. Rev.: Mol. Cell Biol. 11 3 2010 171 181
12. T. de Lange How telomeres solve the end-protection problem Science (New York, N.Y.) 326 5955 2009 948 952
13. M. Kirwan, and I. Dokal Dyskeratosis congenita: a genetic disorder of many faces Clin. Genet. 73 2 2008 103 112
14. N.D. Nelson, and A.A. Bertuch Dyskeratosis congenita as a disorder of telomere maintenance Mutat. Res./Fundam. Mol. Mech. Mutag. 730 1-2 2012 43 51
15. R. Machado-Pinilla, I. Sanchez-Perez, J.R. Murguia, L. Sastre, and R. Perona A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells Blood 111 5 2008 2606 2614
16. R. Machado-Pinilla, J. Carrillo, C. Manguan-Garcia, L. Sastre, A. Mentzer, B.W. Gu, P.J. Mason, and R. Perona Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain Clin. Transl. Oncol.: Off. Publ. Feder. Spanish Oncol. Soc. Natl. Cancer Inst. Mexico 14 10 2012 755 763
17. C. Pinto Reis, R.J. Neufeld, A.J. Ribeiro, and F. Veiga Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems Nanomed. Nanotechnol. Biol. Med. 2 2 2006 53 65
18. S.C. Yadav, A. Kumari, and R. Yadav Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation Peptides 32 1 2011 173 187
19. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Préat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2 2012 505 522
20. R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, and R.H. Muller 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption Colloids Surf., B: Biointerfaces 18 3-4 2000 301 313
21. V. Labhasetwar Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery Curr. Opin. Biotechnol. 16 6 2005 674 680
22. M.∅. Andersen, A. Lichawska, A. Arpanaei, S.M. Rask Jensen, H. Kaur, D. Oupicky, F. Besenbacher, P. Kingshott, J. Kjems, and K.A. Howard Surface functionalisation of PLGA nanoparticles for gene silencing Biomaterials 31 21 2010 5671 5677
23. S. Fischer, E. Uetz-von Allmen, Y. Waeckerle-Men, M. Groettrup, H.P. Merkle, and B. Gander The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles Biomaterials 28 6 2007 994 1004
24. P. Jarver, and U. Langel Cell-penetrating peptides - a brief introduction Biochim. Biophys. Acta 1758 3 2006 260 263
25. J. Farrera-Sinfreu, E. Giralt, S. Castel, F. Albericio, and M. Royo Cell-penetrating cis-gamma-amino-l-proline-derived peptides J. Am. Chem. Soc. 127 26 2005 9459 9468
26. A. Kalinin, N.H. Thoma, A. Iakovenko, I. Heinemann, E. Rostkova, A.T. Constantinescu, and K. Alexandrov Expression of mammalian geranylgeranyltransferase type-II in Escherichia coli and its application for in vitro prenylation of Rab proteins Protein Expr. Purif. 22 1 2001 84 91
27. E. Kaiser, R.L. Colescott, C.D. Bossinger, and P.I. Cook Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides Anal. Biochem. 34 2 1970 595 598
28. R. Fischer, O. Mader, G. Jung, and R. Brock Extending the applicability of carboxyfluorescein in solid-phase synthesis Bioconjug. Chem. 14 3 2003 653 660
29. I. Gutierro, R.M. Hernandez, M. Igartua, A.R. Gascon, and J.L. Pedraz Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres Vaccine 21 1-2 2002 67 77
30. R. Misra, and S.K. Sahoo Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy Eur. J. Pharm. Sci. 39 1-3 2010 152 163
31. K.J. Wiechelman, R.D. Braun, and J.D. Fitzpatrick Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation Anal. Biochem. 175 1 1988 231 237
32. I. Sanchez-Perez, J.R. Murguia, and R. Perona Cisplatin induces a persistent activation of JNK that is related to cell death Oncogene 16 4 1998 533 540
33. I. Youm, and B.C. Youan Uptake mechanism of Furosemide-loaded pegylated nanoparticles by cochlear cell lines Hear. Res. 304 2013 7 19
34. W.E. Wright, J.W. Shay, and M.A. Piatyszek Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity Nucleic Acids Res. 23 18 1995 3794 3795
35. H. Hillaireau, and P. Couvreur Nanocarriers' entry into the cell: relevance to drug delivery Cell. Mol. Life Sci.: CMLS 66 17 2009 2873 2896
36. M.T. Stephan, and D.J. Irvine Enhancing cell therapies from the outside in: cell surface engineering using synthetic nanomaterials Nano Today 6 3 2011 309 325
37. P. Lundberg, and Ü. Langel A brief introduction to cell-penetrating peptides J. Mol. Recognit. 16 5 2003 227 233
38. J.M. Martínez Gómez, N. Csaba, S. Fischer, A. Sichelstiel, T.M. Kündig, B. Gander, and P. Johansen Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis J. Control. Release 130 2 2008 161 167
39. B. Patel, V. Gupta, and F. Ahsan PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin J. Control. Release 162 2 2012 310 320
40. H. Mueller, M.U. Kassack, and M. Wiese Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines J. Biomol. Screen. 9 6 2004 506 515
41. N. Nafee, M. Schneider, U.F. Schaefer, and C.M. Lehr Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile Int. J. Pharm. 381 2 2009 130 139
42. M.D. Shau, M.F. Shih, C.C. Lin, I.C. Chuang, W.C. Hung, W.E. Hennink, and J.Y. Cherng A one-step process in preparation of cationic nanoparticles with poly(lactide-co-glycolide)-containing polyethylenimine gives efficient gene delivery Eur. J. Pharm. Sci. 46 5 2012 522 529
43. L. Chronopoulou, A. Cutonilli, C. Cametti, M. Dentini, and C. Palocci PLGA-based nanoparticles: effect of chitosan in the aggregate stabilization. A dielectric relaxation spectroscopy study Colloids Surf., B: Biointerfaces 97 2012 117 123
44. D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein, and T. Kissel In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis Biomaterials 24 7 2003 1121 1131
45. B.W. Gu, M. Bessler, and P.J. Mason A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice Proc. Natl. Acad. Sci. USA 105 29 2008 10173 10178